Sionna Therapeutics Announces Clinical Trial Data and Strategic Program Update

Sionna Therapeutics, Inc. announced topline data from its PreciSION CF Phase 2a proof-of-concept trial of SION-719 and its Phase 1 trial of SION-451-based proprietary dual combinations. The company stated it is not advancing SION-719 as an add-on to standard of care and plans to preserve capital while evaluating next steps for its SION-451 dual combination program.